Pyxis Oncology Announces FDA Clearance of Two IND Applications
FDA grants IND clearances of PYX-201, a novel antibody-drug conjugate (ADC) product candidate, and PYX-106, an immunotherapy product candidate
Related news for (PYXS)
- MoBot alert highlights: NASDAQ: HTCR, NYSE: LDI, NASDAQ: RLMD, NASDAQ: PYXS, NASDAQ: CIGL (09/05/25 03:00 PM)
- Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
- Today’s Top Performers: MoBot’s Market Review 05/02/25 03:00 PM
- Don’t Miss Out: MoBot’s Latest Stock Updates 05/02/25 02:00 PM
- Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC